KDR and non-small cell lung carcinoma: The cEGFR-cSL partners predict specific response to erlotinib, as opposed to merely predicting patient survival: It failed to predict patients’ response in an independent arm of the same trial in which 37 NSCLC patients were treated with sorafenib, a VEGFR inhibitor (log rank P > 0.95, Supplementary Fig. 9C, D).